Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
March 22, 2004
- Pfizer Working to Boost Motivation, Research Efficiency
March 15, 2004
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
March 15, 2004
- Takeda to Remain No. 1 in Priority Fields under New Marketing System: Mr Yamaoka
March 15, 2004
- Japanese Healthcare Q&A (6)
March 15, 2004
- Yamanouchi to Promote Stasis in Patients with Mild Diabetes
March 15, 2004
- Fujisawa's R&D Pipeline Updated
March 15, 2004
- Banyu to Focus More Resources on Marketing of Fosamac
March 15, 2004
- New GL for Cerebral Apoplexy Released
March 15, 2004
- Teijin Pharma to Expand MR Force to Boost Sales of Bonalon
March 15, 2004
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
March 15, 2004
- Sumitomo: FY2003 Sales to Fall Short of Forecast, but Profits Go as Expected
March 15, 2004
- DIAGNOSTIC NEWS IN BRIEF
March 15, 2004
- Eisai Formally Decides to Adopt "Company with Committees" System
March 15, 2004
- OTC NEWS IN BRIEF
March 15, 2004
- Symposium Discusses Use of Bar Codes to Prevent Medication Errors
March 15, 2004
- WORLD NEWS IN BRIEF
March 15, 2004
- BUSINESS NEWS IN BRIEF
March 15, 2004
- 1st 3 Qtrs Business Results
March 15, 2004
- Nihon Medi-Physics' 123I-iomazenil Recommended for Approval
March 15, 2004
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…